伊痛舒的致突变作用研究  

STUDY ON MUTTAGENICITY OF YI TONG SHU

作　　者：徐德祥[1] 孙美芳[1] 魏凌珍[1] 王取南[1] 余素贞[1] 

机构地区：[1]安徽医科大学卫生毒理教研室

出　　处：《癌变．畸变．突变》1999年第1期42-43,共2页Carcinogenesis,Teratogenesis & Mutagenesis

摘　　要：应用ＣＨＬ细胞染色体畸变试验、Ａｍｅｓ试验和小鼠骨髓嗜多染红细胞微核试验对伊痛舒进行了致突变作用研究。结果显示：０．００６２５ｍｌ／皿、０．０１２５ｍｌ／皿、０．０２５ｍｌ／皿、０．０５ｍｌ／皿、０．１ｍｌ／皿各剂量组ＴＡ９７、ＴＡ９８、ＴＡ１００、ＴＡ１０２各试验菌珠ＭＲ＜２；１２５０ｍｇ／ｋｇ、２５００ｍｇ／ｋｇ、５０００ｍｇ／ｋｇ各剂量组ＰＣＥ微核率分别为２．０‰、２２‰、２８‰，与对照组（４０‰）比较无明显差异（Ｐ＜００５）；０．０１２５ｍｌ／ｍｌ、０．０２５ｍｌ／ｍｌ、０．０５ｍｌ／ｍｌ、０．１ｍｌ／ｍｌ各剂量组加与不加Ｓ９ＣＨＬ细胞染色体畸变率均小于５％。Yi Tong Shu, a Chinese medicine, was examined for mutagenicity with cultured CHL cell chromosome aberration test, Ames test and micronucleus test of PCE in mouse bone marrow. The results showed that Yi Tong Shu with 5 doses (0.00625ml/plate-0.1ml/plate) didn't increase the reversion mutation frequencies in strain TA97, TA98, TA100 and TA102 with or without S9 in the Ames test; It didn't increase the frequencies of micronucleus in PCE and chromosome aberrations in CHL cells.

关 键 词：伊痛舒注射液 致突变作用 中药 

分 类 号：R286.11[医药卫生—中药学] R285.1[医药卫生—中医学]